HC Wainwright Forecasts Palisade Bio Q1 Earnings

Key Points

• HC Wainwright forecasts Q1 2026 EPS of ($0.01), reiterates a Buy rating with a $7.00 price target, and provided quarterly EPS estimates through FY2027 (FY2027 EPS ~ ($0.12)), implying modest per-quarter losses ahead.
• Other firms show mixed but generally positive coverage — Piper Sandler has an overweight call with a $25 target while B. Riley, Stifel and Clear Str issued buy/strong‑buy ratings; MarketBeat’s consensus is a Moderate Buy with an average target of $11.00.
• Palisade’s shares opened at $2.00 (market cap ~$331.8M) and the company remains unprofitable, leaving it exposed to potential future financing/dilution and the typical clinical/regulatory binary risks for biotech stocks; institutional ownership is about 11.8%.

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Palisade Bio in a research report issued on Thursday, March 26th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Palisade Bio's current full-year earnings is ($12.43) per share. HC Wainwright also issued estimates for Palisade Bio's Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.02) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.12) EPS.

Other equities analysts have also issued reports about the stock. B. Riley Financial began coverage on shares of Palisade Bio in a research report on Friday, January 9th. They set a "buy" rating and a $7.00 price target on the stock. Piper Sandler assumed coverage on shares of Palisade Bio in a research note on Monday, December 29th. They issued an "overweight" rating and a $25.00 target price on the stock. Wall Street Zen upgraded Palisade Bio from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Stifel Nicolaus began coverage on Palisade Bio in a research report on Wednesday, February 25th. They issued a "buy" rating and a $5.00 price target for the company. Finally, Clear Str raised Palisade Bio to a "strong-buy" rating in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $11.00.

Palisade Bio Price Performance

Shares of NASDAQ PALI opened at $2.00 on Monday. The firm has a 50-day simple moving average of $1.78 and a 200-day simple moving average of $1.76. The stock has a market capitalization of $331.76 million, a price-to-earnings ratio of -0.94 and a beta of 1.53. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.64.

Hedge Funds Weigh In On Palisade Bio

A number of institutional investors have recently bought and sold shares of PALI. Total Clarity Wealth Management Inc. acquired a new position in Palisade Bio in the 4th quarter valued at about $70,000. Jefferies Financial Group Inc. purchased a new stake in shares of Palisade Bio during the 4th quarter valued at approximately $110,000. Geode Capital Management LLC lifted its holdings in Palisade Bio by 5,780.7% in the fourth quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company's stock valued at $3,681,000 after acquiring an additional 1,538,832 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Palisade Bio in the fourth quarter valued at approximately $1,310,000. Finally, TD Asset Management Inc acquired a new position in Palisade Bio in the fourth quarter valued at approximately $480,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

More Palisade Bio News

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a "Buy" rating and a $7.00 price target — a material upside vs. the current share price that can attract buyer interest and improve sentiment. Palisade Bio NASDAQ: PALI Research Coverage Started at HC Wainwright
• Neutral Sentiment: HC Wainwright published detailed EPS forecasts: quarterly losses in the range of roughly ($0.01)–($0.03) through FY2027 and an FY2027 EPS forecast of about ($0.12). These projected small per-quarter losses suggest the analyst model anticipates limited near-term burn per share, but results will hinge on clinical and business execution. MarketBeat PALI coverage summary
• Negative Sentiment: Palisade remains unprofitable; continued negative EPS implies potential future financing/dilution and exposes the stock to clinical and regulatory binary risks common to biotech names — these are key downside factors for investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.